x
Recognized innovator at the intersection of deep cell science and AI-driven oncology. Our work in true single-cell multi-omics and cell-biopsy technology has received global attention across academia, clinical oncology, and industry.
1Cell.Ai has established itself as a thought leader in oncology through impactful
publications and presentations:
Recent high-impact work includes a 2026 publication in the journal
Cancers regarding multi-omics detection in CTCs
Our technologies are being evaluated and validated across leading global cancer institutions. These collaborations support multi-center validation studies, longitudinal research studies
1Cell is guided by globally recognized scientific and medical leaders.
The distinguished panel of KOLs reinforces 1Cell Ai’s authority as a trusted innovator in the oncology space
Successfully processed 1,700+ validated samples with an 83.3% CTC-positive detection rate across various tumor types.
Patented technology for isolating one-in-a-billion tumor cells.
Led by a team with over 400 years of combined domain expertise and 30+ PhDs.
Strong positioning across clinical diagnostics and biopharma
trial markets
1Cell operates at the intersection of innovation
ecosystems — combining Silicon Valley AI expertise with
scalable clinical and research operations in India.
